Triple-Class Refractory Multiple Myeloma
Recommendations for sequencing therapies for triple-class refractory myeloma with options such as selinexor, belantamab mafodotin, or melflufen.
EP. 3: Establishing a Treatment Plan for Triple-Class Refractory Myeloma
Insight regarding the risk of development of triple-class refractory disease in multiple myeloma and recommendations for working with patients to establish an appropriate treatment plan and counsel on goals of therapy.
EP. 4: Selinexor With Backbone Therapy for Triple-Class Refractory Multiple Myeloma
Considerations for adding selinexor to backbone treatments for triple-class refractory multiple myeloma based on data revealed by the STOMP trial.
EP. 5: Melflufen and Dexamethasone for Triple-Class Refractory Multiple Myeloma
The rationale for adding melflufen to dexamethasone as treatment for patients with triple-class refractory multiple myeloma.
EP. 6: Single-Agent Belantamab Mafodotin for Triple-Class Refractory Multiple Myeloma
An overview of the DREAMM-2 study of belantamab mafodotin for triple-class refractory patients with multiple myeloma, with special considerations for managing treatment-related corneal events.
EP. 7: Individualizing Therapy for Triple-Class Refractory Myeloma
Guidance regarding proper treatment selection and sequencing of therapies for triple-class refractory multiple myeloma.
EP. 8: Addressing Unmet Needs for Triple-Class Refractory Multiple Myeloma
Current unmet needs surrounding the management of patients with triple-class refractory multiple myeloma with newer novel therapies.
EP. 9: Novel Therapies Under Study for Triple-Class Refractory Multiple Myeloma
Novel therapies in clinical development to improve outcomes for patients with triple-class refractory multiple myeloma.
